secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0001193125-23-147667
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

President/COO Neil Klompas to leave Zymeworks June 30; CEO Galbraith becomes President
--------------------------------------------------------------------------------

- Departure of President and COO Neil Klompas effective June 30, 2023; consulting agreement through June 30, 2025.
- Separation includes $1M lump sum (24 months salary), continued benefits for 24 months, and stock vesting continuation.
- CEO Kenneth Galbraith appointed as President in addition to CEO and Chair roles, effective June 30.
- Galbraith has over 35 years of biotech executive experience; his compensation terms remain unchanged.
- Klompas had been with Zymeworks since 2007, serving as CFO, COO, and President.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523147667/0001193125-23-147667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523147667/d445207d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-147667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer